Literature DB >> 14675416

Hepatocellular carcinoma in the thalassaemia syndromes.

Caterina Borgna-Pignatti1, Gianluca Vergine, Turi Lombardo, Maria Domenica Cappellini, Paolo Cianciulli, Aurelio Maggio, Disma Renda, Maria Eliana Lai, Antonella Mandas, Gianluca Forni, Antonio Piga, Maria Grazia Bisconte.   

Abstract

Hepatocellular carcinoma (HCC) frequently complicates hepatic cirrhosis secondary to viral infection or iron overload. Therefore, patients affected by thalassaemia syndromes have a theoretically high risk of developing the tumour. We collected data on patients attending Italian centres for the treatment of thalassaemia. Twenty-two cases of HCC were identified; 15 were male. At diagnosis, the mean age was 45 +/- 11 years and the mean serum ferritin was 1764 +/- 1448 microg/l. Eighty-six percent had been infected by hepatitis C virus. Nineteen of 22 cases were diagnosed after 1993, suggesting that this problem is becoming more frequent with the aging population of thalassaemia patients.

Entities:  

Mesh:

Year:  2004        PMID: 14675416     DOI: 10.1046/j.1365-2141.2003.04732.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  33 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  In search of the optimal iron chelation therapy for patients with thalassemia major.

Authors:  Vasilios Berdoukas; John Wood
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

3.  The life of patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 4.  Non-viral causes of hepatocellular carcinoma.

Authors:  Wojciech Blonski; David S Kotlyar; Kimberly A Forde
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

5.  Non-viral factors contributing to hepatocellular carcinoma.

Authors:  Manal A Hamed; Sanaa A Ali
Journal:  World J Hepatol       Date:  2013-06-27

Review 6.  Measurement of liver fat fraction and iron with MRI and MR spectroscopy techniques.

Authors:  Puneet Sharma; Maria Altbach; Jean-Philippe Galons; Bobby Kalb; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 7.  Hepatic iron overload and hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

Review 8.  Beta-thalassemia.

Authors:  Renzo Galanello; Raffaella Origa
Journal:  Orphanet J Rare Dis       Date:  2010-05-21       Impact factor: 4.123

9.  Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C.

Authors:  Naoki Fujita; Yoshiyuki Takei
Journal:  J Gastroenterol       Date:  2007-11       Impact factor: 7.527

10.  The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

Authors:  Vasilios Berdoukas; Giorgos Chouliaras; Panagiotis Moraitis; Kirykos Zannikos; Eleni Berdoussi; Vassilios Ladis
Journal:  J Cardiovasc Magn Reson       Date:  2009-06-28       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.